Business Wire

ISLAMIC-DEVELOPMENT-BANK

13.5.2023 11:26:30 CEST | Business Wire | Press release

Share
Global Partnerships and Sustainable Financing Top Agenda at IsDB Group 2023 Annual Meetings in Jeddah

Policymakers and business leaders from around the world are deliberating over how to tackle obstacles to sustainable development during the Islamic Development Bank (IsDB) Group’s Annual Meetings underway in Jeddah, Kingdom of Saudi Arabia.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230513005002/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Islamic Development Bank (IsDB) President and Group Chairman, H.E. Dr. Muhammad Al Jasser (Photo: AETOSWire)

Held under the theme, “Partnerships to Fend off Crises,” the 48th edition of the annual meetings has brought together high-ranking government officials and senior business executives to discuss a range of topics such as poverty alleviation, healthcare, education, women and youth empowerment, food security, and climate change.

The four-day event includes both high-level plenary sessions and technical symposiums, to identify effective solutions for economic and development issues faced by the IsDB Group’s 57 member countries (MCs) and its partners.

On the opening day on Wednesday, the IsDB Group Boards Meeting approved financing valued at more than US$558 million for six projects in member countries. The projects focus on supporting inclusive growth and infrastructure development in line with the Sustainable Development Goals (SDGs). The day also witnessed the launch of the ‘IsDB Group Integration Report for Arab Region,’ which measures the progress of economic integration within the Arab region and provides a framework to strengthen trade between the Bank’s MCs.

While the side events of this major event are well underway from 10 May, the official opening ceremony of the event was held on Thursday. Delivering the keynote address, H.E. Dr. Muhammad Al Jasser, President and Group Chairman of IsDB, reaffirmed the Bank Group’s commitment to promoting resilience and providing financing within MCs to help overcome challenges in the backdrop of shifting monetary conditions.

“To support its member countries in tackling crises, the IsDB Group has launched several ambitious initiatives, including a program to address the effects of the pandemic with an amount of USD 4.3 billion, which we have fully implemented, and the Food Security Response Program valued at more than USD 10 billion over the next three years, in addition to committing to contributing to climate finance with an amount of at least USD 13 billion until 2030.”

Meanwhile, the IsDB Group Private Sector Forum, which is taking place from 11-13 May on the sidelines of the annual meetings, is paving the way for stronger public-private partnerships that drive inclusive development and support innovative, sustainable financing.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230513005002/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release

In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release

IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye